Literature DB >> 11918073

Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F-12509A and B-5354c.

Keita Kono1, Masako Sugiura, Takafumi Kohama.   

Abstract

Mesh:

Substances:

Year:  2002        PMID: 11918073     DOI: 10.7164/antibiotics.55.99

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  10 in total

1.  Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Authors:  Yanjun Shi; Hasibur Rehman; Venkat K Ramshesh; Justin Schwartz; Qinlong Liu; Yasodha Krishnasamy; Xun Zhang; John J Lemasters; Charles D Smith; Zhi Zhong
Journal:  J Hepatol       Date:  2011-07-12       Impact factor: 25.083

Review 2.  Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors.

Authors:  K Alexa Orr Gandy; Lina M Obeid
Journal:  Biochim Biophys Acta       Date:  2012-07-16

Review 3.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 4.  Targeting sphingosine-1-phosphate in hematologic malignancies.

Authors:  Christina E Stevenson; Kazuaki Takabe; Masayuki Nagahashi; Sheldon Milstien; Sarah Spiegel
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

Review 5.  Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Authors:  Dmitri Pchejetski; Torsten Böhler; Justin Stebbing; Jonathan Waxman
Journal:  Nat Rev Urol       Date:  2011-09-13       Impact factor: 14.432

Review 6.  Sphingosine 1-phosphate and cancer.

Authors:  Nigel J Pyne; Susan Pyne
Journal:  Nat Rev Cancer       Date:  2010-06-17       Impact factor: 60.716

7.  Delta-catenin/NPRAP (neural plakophilin-related armadillo repeat protein) interacts with and activates sphingosine kinase 1.

Authors:  Toshitada Fujita; Taro Okada; Shun Hayashi; Saleem Jahangeer; Noriko Miwa; Shun-ichi Nakamura
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

8.  Activation of SphK1 by K6PC-5 Inhibits Oxygen-Glucose Deprivation/Reoxygenation-Induced Myocardial Cell Death.

Authors:  Jun-jie Shao; Yi Peng; Li-ming Wang; Jian-kai Wang; Xin Chen
Journal:  DNA Cell Biol       Date:  2015-08-26       Impact factor: 3.311

Review 9.  The emerging role of FTY720 (Fingolimod) in cancer treatment.

Authors:  Christopher White; Heba Alshaker; Colin Cooper; Matthias Winkler; Dmitri Pchejetski
Journal:  Oncotarget       Date:  2016-04-26

10.  Field template-based design and biological evaluation of new sphingosine kinase 1 inhibitors.

Authors:  Heba Alshaker; Shyam Srivats; Danielle Monteil; Qi Wang; Caroline M R Low; Dmitri Pchejetski
Journal:  Breast Cancer Res Treat       Date:  2018-07-24       Impact factor: 4.872

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.